ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
ORAL TESTOSTERONE VERSUS TOPICAL TESTOSTERONE: LARGER DECREASES IN HDL
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 222686" data-attributes="member: 13851"><p><strong>CHANGES IN METABOLIC PARAMETERS AND BONE MARKERS WITH ORAL VERSUS TOPICAL TESTOSTERONE (2022)</strong></p><p><em>Fiona Yuen, Ronald S Swerdloff, Robert Dudley, and Christina Wang The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA; Clarus Therapeutics, Northbrook, IL</em></p><p></p><p></p><p><strong>Background: </strong><em>Oral testosterone undecanoate (TU) was recently evaluated for safety and efficacy in an open-label study in comparison with topical testosterone (T).</em></p><p></p><p><strong>Methods:</strong> <em>Hypogonadal men 18-65 yrs were randomized to oral TU or topical T for approximately 4 months. The starting dose was 237 mg TU twice daily and 60 mg topical T daily. Doses were titrated on Days 21 and 56. P1NP, CTX, and fasting insulin levels from baseline and the last visit (mean 142 days) were analyzed using stored samples in a subset of participants without diabetes. Hematocrit, systolic blood pressure (average of 3 measurements), HDL-C, LDL-C, and fasting glucose were previously assayed and the data are now assessed for changes from baseline and differences between the two drugs using linear mixed model analyses. Outliers (>3 IQR from 25th or 75th percentile) were excluded from the analyses. </em></p><p></p><p><strong>Results:</strong> <em>203 of 222 participants completed the study (154 oral, 49 topical). Total T increased in both groups with treatment (oral, baseline 207 to 489 ng/dL; topical, baseline 204 to 383 ng/dL). SBP (oral, 2.61 ± 11.86; topical, 1.88 ± 9.81 mmHg) and hematocrit increased (oral, 6.0 ± 7.5%; topical, 4.6 ± 6.4%). HDL-C (oral, - 14.2 ± 15.5%; topical, -2.4 ± 16.2%) and total cholesterol decreased (oral, -4.3 ± 16.5%; topical, -4.6 ± 12.0%) (all p<0.001). HDL-C decreased to a greater extent with oral TU (p<0.001). LDL-C increased with oral TU but decreased with topical T (oral, 6.3 ± 26.5%; topical, -1.5 ± 18.0%; p = 0.014); this result was not significant after Bonferroni correction. There were no significant changes in triglycerides, glucose, insulin, P1NP, and CTX. </em></p><p></p><p><strong>Conclusion:</strong> <em><strong>Both formulations decreased HDL-C and total cholesterol and increased SBP and hematocrit. HDL-C decreased to a greater extent with oral TU. Metabolic changes should be assessed for longer durations in larger studies.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 222686, member: 13851"] [B]CHANGES IN METABOLIC PARAMETERS AND BONE MARKERS WITH ORAL VERSUS TOPICAL TESTOSTERONE (2022)[/B] [I]Fiona Yuen, Ronald S Swerdloff, Robert Dudley, and Christina Wang The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA; Clarus Therapeutics, Northbrook, IL[/I] [B]Background: [/B][I]Oral testosterone undecanoate (TU) was recently evaluated for safety and efficacy in an open-label study in comparison with topical testosterone (T).[/I] [B]Methods:[/B] [I]Hypogonadal men 18-65 yrs were randomized to oral TU or topical T for approximately 4 months. The starting dose was 237 mg TU twice daily and 60 mg topical T daily. Doses were titrated on Days 21 and 56. P1NP, CTX, and fasting insulin levels from baseline and the last visit (mean 142 days) were analyzed using stored samples in a subset of participants without diabetes. Hematocrit, systolic blood pressure (average of 3 measurements), HDL-C, LDL-C, and fasting glucose were previously assayed and the data are now assessed for changes from baseline and differences between the two drugs using linear mixed model analyses. Outliers (>3 IQR from 25th or 75th percentile) were excluded from the analyses. [/I] [B]Results:[/B] [I]203 of 222 participants completed the study (154 oral, 49 topical). Total T increased in both groups with treatment (oral, baseline 207 to 489 ng/dL; topical, baseline 204 to 383 ng/dL). SBP (oral, 2.61 ± 11.86; topical, 1.88 ± 9.81 mmHg) and hematocrit increased (oral, 6.0 ± 7.5%; topical, 4.6 ± 6.4%). HDL-C (oral, - 14.2 ± 15.5%; topical, -2.4 ± 16.2%) and total cholesterol decreased (oral, -4.3 ± 16.5%; topical, -4.6 ± 12.0%) (all p<0.001). HDL-C decreased to a greater extent with oral TU (p<0.001). LDL-C increased with oral TU but decreased with topical T (oral, 6.3 ± 26.5%; topical, -1.5 ± 18.0%; p = 0.014); this result was not significant after Bonferroni correction. There were no significant changes in triglycerides, glucose, insulin, P1NP, and CTX. [/I] [B]Conclusion:[/B] [I][B]Both formulations decreased HDL-C and total cholesterol and increased SBP and hematocrit. HDL-C decreased to a greater extent with oral TU. Metabolic changes should be assessed for longer durations in larger studies.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
ORAL TESTOSTERONE VERSUS TOPICAL TESTOSTERONE: LARGER DECREASES IN HDL
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top